The Food and Drug Administration yesterday released a safety notice announcing a software patch is available to address ...

The government’s top vaccine official, working under Health Secretary Robert F. Kennedy Jr., restricted the approval of two ...

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Cobenfy: A Key Growth Driver One of the most significant developments for Bristol-Myers Squibb has been the launch and performance of Cobenfy, its new drug for schizophrenia.

In September 2024, the FDA approved Cobenfy, an oral medication for schizophrenia in adults. Data from the EMERGENT clinical program supported the FDA approval of Cobenfy.